Sustained HBsAg Clearance in HBeAg-Negative Patients Treated with Peg-IFNα-2b

A retrospective study of 203 HBeAg-negative patients with low baseline HBsAg levels treated with Peg-IFNα-2b therapy. The dataset likely contains patient outcomes, including HBsAg reversion rates and associated risk factors, with a median follow-up duration of 96 weeks. It was authored by Chaojing Wen and uploaded to figshare in May 2026.

Use Cases

• Predicting sustained HBsAg clearance based on end-of-treatment HBsAb levels and consolidation therapy duration.
• Analyzing the risk factors for HBsAg reversion using Cox regression models.
• Evaluating the optimal follow-up duration for patients achieving HBsAg clearance.
• Studying the relationship between HBsAb levels and long-term treatment success rates.

Strengths

• Includes data from 203 patients, providing a specific cohort size.
• Reports a median follow-up duration of 96 weeks (range 72-120 weeks), offering a defined observation period.
• Identifies specific quantitative predictors, such as EOT HBsAb >1000 IU/mL correlating with a 100% sustained clearance rate.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or institutional bias inherent to a single retrospective study.

Provenance

Source

figshare, author Chaojing Wen.

Collection Method

Retrospective study analyzing patient records.

Time Range

The study follow-up period had a median of 96 weeks.

Freshness

Last updated 2026-05-20 10:43:28; freshness should be verified.